Amorphous tecovirimat preparation
Inventors
Tyavanagimatt, Shanthakumar R. • Samuel, N K Peter • PAZ, Joseph • Tan, Ying • Hruby, Dennis E.
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Disclosed are methods for the preparation of amorphous N-[(3aR,4R,4aR,5aS,6S,6aS)-3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl]-4-(trifluoromethyl)-benzamide for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases caused by the orthopoxvirus. Also disclosed are methods for the preparation of amorphous solid dispersion of N-[(3aR,4R,4aR,5aS,6S,6aS)-3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl]-4-(trifluoromethyl)-benzamide.
Core Innovation
The disclosed method produces amorphous tecovirimat (ST-246) from a solid form by melting and cooling the melted form; [procedural detail omitted for safety]. The identified starting solid materials include crystalline Forms I and III, including a monohydrate. The resulting amorphous product is characterized as exhibiting an X-ray powder diffraction halo pattern indicating a non-crystalline state.
The disclosure indicates that amorphous ST-246 provides faster dissolution and supersaturation compared to crystalline forms. These properties potentially enable a reduced active pharmaceutical dosage while mitigating food effect and pharmacokinetic variability. Accordingly, the amorphous product is described as offering enhanced solubility and improved therapeutic exposure characteristics.
Claims Coverage
The claim coverage includes one inventive feature directed to the preparation of amorphous tecovirimat. It covers producing amorphous tecovirimat from a solid form, with dependent claims further specifying cooling conditions and starting solid forms.
Production of amorphous tecovirimat
A method for producing amorphous tecovirimat by heating a solid form until it melts and cooling the melted form; [procedural detail omitted for safety]. Dependent claims further define cooling conditions and identify starting solid forms, including a monohydrate and Form I characterized by an X-ray powder diffraction pattern.
The claim coverage centers on producing amorphous tecovirimat from a solid form and includes dependent limitations concerning cooling and the identity or characterization of the starting solid form.
Stated Advantages
Amorphous ST-246 provides faster dissolution and supersaturation, potentially enabling a reduced dosage and reducing food effect and pharmacokinetic variability.
Documented Applications
Production of amorphous tecovirimat (ST-246) from a solid form.
Interested in licensing this patent?